About

TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. About TaiMed Biologics TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. About TaiMed Biologics TaiMed Biologics & Orient EuroPharma — Your Trusted Partners in Biologics and CDMO Services TaiMed Biologics (TaiMed) is a leading biopharmaceutical company specializing in the development and manufacturing of innovative biologics, with a strong focus on anti-HIV therapies. Our Key Strengths Include: - First-in-Class Innovation: Developer of Trogarzo® (ibalizumab), the world’s first long-acting monoclonal antibody for HIV, approved by the US FDA and EMA in 2018 and 2019. - Next-Gen HIV Therapies: Advancing long-acting monoclonal antibodies for HIV treatment and prevention. - Clinical-Stage Leadership: Leading candidate TMB-365/380 received Fast Track Designation from the US FDA in 2023 and has successfully completed Phase 2a, showing promising potential as a more confirming and durable HIV therapy. - Partnering Opportunities: Actively seeking global licensing and co-development partnerships with companies focused on HIV therapy. - CDMO Services: Leveraging decades of antibody development experience, TaiMed now offers end-to-end CDMO solutions, from early-stage development through to commercial manufacturing. This year, TaiMed is proud to co-exhibit with our long-term partner, Orient EuroPharma (OEP), to present integrated, high-quality biomanufacturing solutions that meet global standards. About Orient EuroPharma (OEP) Founded in 1982, Orient EuroPharma (OEP) is a Taiwan-based multinational pharmaceutical company specializing in prescription medicines, nutricare, and anti-aging products. OEP also offers comprehensive CDMO services, providing expertise from formulation development to commercial-scale finished product manufacturing. OEP’s CDMO capabilities include: - Formulation Development: Expertise in controlled-release formulations - Oral Dosage Manufacturing: Tablet, Capsule (granule/pellets/semi-solid/liquid filling) - Injectable Manufacturing: Liquid and lyophilized vials for high potency, cytotoxic and non-cytotoxic product Why Partner with OEP? - Regulatory Excellence: 15+ successful IND submissions in the U.S., China, and Taiwan; NDA projects ongoing - U.S.-Based R&D (San Diego Lab): Local formulation development & small-scale batch production for faster collaboration - Advanced Capsule Technology: Specialized in semisolid/liquid filling and banding for enhanced drug stability -Flexible Manufacturing Scale: Seamless transition from small-batch IND to large-scale NDA production - Quality Certification: Facilities certified by US FDA, PIC/S GMP, TGA, and MHRA With a strong track record of innovation, regulatory success, and manufacturing quality, TaiMed and OEP together offer a powerful CDMO partnership to support your drug development and commercialization goals. Visit us at our booth to explore collaborative opportunities!